Jw Life Science Corp (234080) - Total Assets
Based on the latest financial reports, Jw Life Science Corp (234080) holds total assets worth ₩305.78 Billion KRW (≈ $207.23 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jw Life Science Corp - Total Assets Trend (2015–2025)
This chart illustrates how Jw Life Science Corp's total assets have evolved over time, based on quarterly financial data. Also see Jw Life Science Corp (234080) total market value for the company's overall valuation and market capitalisation.
Jw Life Science Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Jw Life Science Corp's total assets of ₩305.78 Billion consist of 27.8% current assets and 72.3% non-current assets. Review Jw Life Science Corp total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.6% |
| Accounts Receivable | ₩43.23 Billion | 13.6% |
| Inventory | ₩31.62 Billion | 9.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩44.68 Billion | 14.0% |
| Goodwill | ₩32.39 Billion | 10.2% |
Asset Composition Trend (2015–2025)
This chart illustrates how Jw Life Science Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Jw Life Science Corp stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jw Life Science Corp's current assets represent 27.8% of total assets in 2025, an increase from 21.6% in 2015.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2025, up from 0.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 14.0% of total assets.
Jw Life Science Corp Competitors by Total Assets
Key competitors of Jw Life Science Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
Germany | €128.04 Billion |
Jw Life Science Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 1.13 | 0.85 |
| Quick Ratio | 0.81 | 0.75 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩16.53 Billion | ₩11.68 Billion | ₩-10.69 Billion |
Jw Life Science Corp - Advanced Valuation Insights
This section examines the relationship between Jw Life Science Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.75 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.2% |
| Total Assets | ₩318.21 Billion |
| Market Capitalization | $115.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jw Life Science Corp's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jw Life Science Corp's assets decreased by 2.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jw Life Science Corp (2015–2025)
The table below shows the annual total assets of Jw Life Science Corp from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩318.21 Billion ≈ $215.64 Million |
-2.19% |
| 2024-12-31 | ₩325.32 Billion ≈ $220.47 Million |
+27.16% |
| 2023-12-31 | ₩255.84 Billion ≈ $173.38 Million |
+1.14% |
| 2022-12-31 | ₩252.94 Billion ≈ $171.42 Million |
+15.25% |
| 2021-12-31 | ₩219.47 Billion ≈ $148.73 Million |
+0.65% |
| 2020-12-31 | ₩218.04 Billion ≈ $147.76 Million |
+8.26% |
| 2019-12-31 | ₩201.40 Billion ≈ $136.49 Million |
+0.27% |
| 2018-12-31 | ₩200.86 Billion ≈ $136.12 Million |
+1.17% |
| 2017-12-31 | ₩198.53 Billion ≈ $134.54 Million |
+3.27% |
| 2016-12-31 | ₩192.24 Billion ≈ $130.28 Million |
+6.87% |
| 2015-12-31 | ₩179.88 Billion ≈ $121.90 Million |
-- |
About Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed … Read more